Nanomedicine-based doxorubicin delivery for skin cancer with theranostic potential

Abstract

Abstract The expectancy of life has been increasing in the Western world since long time due to optimal standards of life, good hygienic conditions, and, of course, advancement in modern medicine. The current chapter provides a brief overview of nanotechnology-based treatment approaches for skin cancer. Unique physicochemical characteristics and biomedical advancement for the development of nanocarriers have provided applications in targeting drug delivery, diagnosis, and patient compliance. Doxorubicin (DOX) biodegradable and biocompatible nanocarrier systems have shown enhanced bioavailability, therapeutic index, and thus, reduced treatment costs. For instance, the date of doxorubicin-loaded quaternary ammonium palmitoyl glycol chitosan (DOX-GCPQ) particles serves as translational link for clinical trials assessing anticancer efficacy and diagnostic potential, via DOX optical imaging of formulation after appropriate testing and guidance for further studies, leading to clinical evaluation to determine safety margins of formulation.